H. Lee Moffitt Cancer Center & Research Institute

SEPTEMBER/OCTOBER 2001

Vol 8, No 5 CME Pretest

In this issue, the topic of breast cancer is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

  • recognize the role of MRI in breast imaging and of the sentinel node procedure in staging,

  • understand the current status of breast reconstruction approaches,

  • manage postoperative pain,

  • prescribe treatment for elderly patients, and

  • address treatment-induced sexual problems.

Also, they will be able to recognize the symptoms and findings in carcinoid heart disease.

This program was planned in accordance with ACCME Essentials.

Release Date: September 1, 2001
Expiration Date: September 1, 2002


Pretest

1. What procedure is the standard pathology evaluation of resected axillary lymph nodes in breast cancer patients in the United States?


a. cytokeratin analysis of serial sections
b. single section with H&E stain
c. 10 sections/node with H&E stain
d. serial section of all nodes with H&E stain

2. Which approach to breast reconstruction is the best option when postmastectomy radiation is included in the treatment program?

a. autologous reconstruction with TRAM or latissimus dorsi flap
b. immediate reconstruction with tissue expanders
c. delayed reconstruction with tissue expanders
d. none of the above

3. The International Breast Cancer Study Group studied the use of CMF as an adjuvant therapy for postmenapausal women with breast cancer. Benefits declined with increasing age and disappeared after age:

a. 75
b. 65
c. 55
d. 45

 




© Copyright 1996 - 2012 H. Lee Moffitt Cancer Center & Research Institute